Search

Search Results

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1739

  PDF: 669

  HTML: 94
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1306

  PDF: 405

  HTML: 45

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  989

  PDF: 521

  SUPPLEMENTARY MATERIAL: 153

  HTML: 16
• 

  Erythrodermic psoriasis improved by tildrakizumab

  Giampaolo Trevisan, Lerica Germi, Luigi Naldi

  23-11-2022

  https://doi.org/10.4081/dr.2022.9448

  1139

  PDF: 620

  HTML: 21

• Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis

  Davide Bertolla, Andrea Conti

  30-01-2026

  https://doi.org/10.4081/dr.2026.10240

  872

  PDF: 281
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1057

  PDF: 546

  HTML: 19
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1162

  PDF: 825

  HTML: 41

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  792

  PDF: 460

  HTML: 17

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  884

  PDF: 543

  HTML: 32

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  532

  PDF: 301
• 

  A case of squamous cell carcinoma arising in a giant porokeratosis previously diagnosed as psoriasis

  Lorry Aitkens, Joel Byrne, Charay Jennings-Dover, Kathryn Anne Potter

  29-12-2022

  https://doi.org/10.4081/dr.2023.9634

  920

  PDF: 445

  HTML: 121

• Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

  Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili

  13-03-2025

  https://doi.org/10.4081/dr.2025.10021

  441

  PDF: 304

  HTML: 7